Board Meeting Outcome for adoption of Unaudited Financial Results for the half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.6 pts less than Nifty Microcap 250 and 3.3 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Transpact Enterprises' board, at its meeting on November 14, 2025, approved the unaudited standalone financial results for H1 FY26 (ended September 30, 2025). Revenue from operations rose to Rs 9.50 lakhs from Rs 7.00 lakhs in the same period last year, a growth of about 36%. The company swung from a loss before tax of Rs 5.08 lakhs in H1 FY25 to a profit before tax of Rs 4.94 lakhs in H1 FY26, with EPS of Rs 0.13 versus a negative Rs 0.13 earlier. Total balance sheet size stood at Rs 72.95 lakhs (vs Rs 70.03 lakhs as on March 31, 2025). Statutory auditor NGMKS & Associates issued an unmodified (clean) review opinion. The company noted it has carry-forward losses and unabsorbed depreciation, so no current or deferred tax has been computed.
A clear turnaround from loss to profit along with double-digit revenue growth and a clean audit opinion is a positive signal for shareholders, though the absolute numbers remain small, indicating the company is still at a nascent scale. Short-term stock reaction may be mildly positive given the earnings swing, but investors should watch for sustained growth.